Abstract:Chemokine receptor CCR2 is a member of the seven-transmembrane G-protein-coupled receptor superfamily, and is predominantly expressed on monocytes and macrophages. The interaction of the chemokine CCL2 with the CCR2 plays an important role in the recruitment of monocytes, natural killer cells, dendritic cells and T-lymphocytes. Recent studies have linked the CCL2/CCR2 axis to various inflammatory diseases such as rheumatoid arthritis, multiple sclerosis, atherosclerosis, diabetes and even cancer. Thus, small molecule antagonists which can block the binding of CCR2 and CCL2 represent new therapeutic interventions of the inflammation-related diseases. By comprehensively analyzing the structures of the literature-reported potent CCR2 antagonists, we concluded a pharmacophore model for CCR2 inhibition, including a basic amino center, a hydrophobic aromatic ring on the right-hand side, and an amide group which serves as a hydrogen bond acceptor and a hydrogen bond donor. Then we performed the lead deconstruction and pharmacophore model-based privileged fragment reassembly strategy to discover new scaffold small molecule CCR2 inhibitors. The lead-like privileged scaffolds of alpha-alkyl-gamma-aminobutanamide and glycinamide were selected to combine with novel aromatic moiety and amide portion, delivering 3 classes of new structure CCR2 inhibitors. Total 11 compounds were designed and synthesized via a facile convergent synthetic procedure. The CCR2 antagonism activity evaluation revealed that N-(3-aminocyclopentane-carboxamido) methyl) benzamide was an active scaffold (exemplified by 1a, IC50= 25 nmol/L). The preliminary structure-activity relationship study indicated that the basic amino group and the lipophilic aliphatic moiety and small size aromatic group are important for the interaction with CCR2 protein. The replacement of the basic amino group with an amide would lead to the significant loss of the activity. This work provides a promising new structure CCR2 inhibitor and useful SAR conclusions which will promote the further development of CCR2 inhibitor into drug candidate.

Synthesis of Arylaminothiazole Derivatives and Their CCR4 Inhibitory Activity

Design, Synthesis and SAR Study of Novel Trisubstituted Pyrimidine Amide Derivatives As CCR4 Antagonists

Design and Synthesis of Tri‐substituted Chiral Pyrrolidin‐2‐one Derivatives As CCR4 Antagonists

Screening of Thiourea Derivatives and Carbonyl-2-aminothiazole Derivatives for Potential CCR4 Antagonists Using Capillary Zone Electrophoresis

Design and synthesis of a series of pyrido[2,3-d]pyrimidine derivatives as CCR4 antagonists.

Design, Synthesis, and Evaluation of Novel CXCR4 Antagonists Based on an Aminoquinoline Template.

Synthesis and Biological Activities of Novel 2-Amino-1,3-thiazole-4-carboxylic Acid Derivatives

Pharmacophore Model-based Design and Synthesis of New Structure Small Molecule CCR2 Inhibitors

Synthesis and biological activity of carbamoyl substituted phenoxylalkylamine derivatives

Synthesis and Biological Activity of 1-(1,4-benzodioxan-2-yl-carbonyl)-4-aryloxy-alkyl-piperazine As Α_1-Adrenoceptor Antagonists

Design, Synthesis, and Characterization of Novel CXCR4 Antagonists Featuring Cyclic Amines

Synthesis and Cytotoxicity in Vitro of N-Aryl-4-(Tert-Butyl)-5-(1h-1,2,4-Triazol-1-Yl)Thiazol-2-Amine

[Synthesis and Antitumor Activity of Arylsubstituted Imidazolin-2-one Derivatives].

Design, Synthesis, and Biological Activities of Arylmethylamine Substituted Chlorotriazine and Methylthiotriazine Compounds.

Synthesis and biological evaluation of spirocyclic antagonists of CCR2 (chemokine CC receptor subtype 2)

Synthesis and Biological Activity of Novel Imidazo[2,1-b] [1,3,4] thiadiazole Derivatives

Synthesis and biological activity of novel anthranilic diamides containing N -substituted arylmethylene moieties

Synthesis and Biological Activity of 4-Methyl-1,2,3-thiadiazole-5-carboxylates

Synthesis and blocking activities of a new class of α₁-adrenoceptor antagonists.

Synthesis and biological evaluation of 3,4-diaryl-5-aminoisoxazole derivatives.

Synthesis, biological evaluation and 3D-QSAR study of 1-(1,4-benzodioxan-2-ylcaronyl)-4-aryloxyalkyl-piperazines as α1-adrenoceptor antagonists